KalVista Pharmaceuticals, Inc. (KALV) Financial Statements (2026 and earlier)

Company Profile

Business Address 200 CROSSING BOULEVARD
FRAMINGHAM, MA 01702
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
MRQ
4/30/2025
4/30/2024
4/30/2023
4/30/2022
4/30/2021
4/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments220,617210,401149,375166,202248,92967,714
Cash and cash equivalent131,61531,78956,23830,73250,59215,789
Short-term investments89,002178,61293,137135,470198,33751,925
Restricted cash and investments657     
Receivables9321,0231,4221,821  
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Prepaid expense 8071,5851,7248,404  
Other undisclosed current assets18,67712,68119,80517,22015,33520,982
Total current assets:241,690225,690172,326193,647264,26488,696
Noncurrent Assets
Operating lease, right-of-use asset5,5446,9207,8227,8625,7581,612
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization1,9882,2272,9482,1781,7912,043
Other noncurrent assets1,548567106193200178
Total noncurrent assets:9,0809,71410,87610,2337,7493,833
TOTAL ASSETS:250,770235,404183,202203,880272,01392,529
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32,19021,50513,94514,7678,9117,132
Employee-related liabilities4,168  
Accounts payable4,8839,1074,8173,6381,9811,677
Accrued liabilities27,30712,3989,1286,9616,9305,455
Deferred revenue11,000     
Debt      588
Other undisclosed current liabilities1,9771,3021,087(3,191)863 
Total current liabilities:45,16722,80715,03211,5769,7747,720
Noncurrent Liabilities
Long-term debt and lease obligation   7,2115,0461,057
Long-term debt, excluding current maturities      
Liabilities, other than long-term debt4,3306,0157,145   
Operating lease, liability4,3306,0157,1457,2115,0461,057
Other undisclosed noncurrent liabilities105,882  (7,211)(5,046) 
Total noncurrent liabilities:110,2126,0157,1457,2115,0461,057
Total liabilities:155,37928,82222,17718,78714,8208,777
Equity
Equity, attributable to parent95,391206,582161,025185,093257,19383,752
Common stock504234252418
Additional paid in capital753,725679,754507,133439,104426,437207,208
Accumulated other comprehensive loss(5,214)(3,488)(3,060)(3,861)(1,432)(1,882)
Accumulated deficit(653,170)(469,726)(343,082)(250,175)(167,836)(121,592)
Total equity:95,391206,582161,025185,093257,19383,752
TOTAL LIABILITIES AND EQUITY:250,770235,404183,202203,880272,01392,529

Income Statement (P&L) ($ in thousands)

9/30/2025
TTM
4/30/2025
4/30/2024
4/30/2023
4/30/2022
4/30/2021
4/30/2020
Revenues1,6001,300   12,690
Gain on disposition of assets for financial service operations 1,6001,300    
Cost of revenue
(Cost of Product and Service Sold)
      
Gross profit:1,6001,300   12,690
Operating expenses(187,995)(140,445)(110,871)(96,613)(57,923)(53,223)
Other undisclosed operating income (loss)(1,600)(1,300)    
Operating loss:(187,995)(140,445)(110,871)(96,613)(57,923)(40,533)
Nonoperating income7,94313,80117,96414,27411,67911,293
Investment income, nonoperating6,4353,8962,2321,0909031,830
Gain (loss), foreign currency transaction, before tax2,48113890(1,537)847(367)
Other nonoperating income4,8129,76715,64214,7219,9299,830
Interest and debt expense(5,785)     
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(185,837)(126,644)(92,907)(82,339)(46,244)(29,240)
Other undisclosed income from continuing operations before income taxes5,785     
Loss from continuing operations before income taxes:(180,052)(126,644)(92,907)(82,339)(46,244)(29,240)
Income tax expense (benefit)(3,392)    124
Loss from continuing operations:(183,444)(126,644)(92,907)(82,339)(46,244)(29,116)
Loss before gain (loss) on sale of properties:(82,339)(46,244)(29,116)
Net loss available to common stockholders, diluted:(183,444)(126,644)(92,907)(82,339)(46,244)(29,116)

Comprehensive Income ($ in thousands)

9/30/2025
TTM
4/30/2025
4/30/2024
4/30/2023
4/30/2022
4/30/2021
4/30/2020
Net loss:(183,444)(126,644)(92,907)(82,339)(46,244)(29,116)
Other comprehensive income (loss)(1,726)(428)801(2,429)450 
Comprehensive loss:(185,170)(127,072)(92,106)(84,768)(45,794)(29,116)
Other undisclosed comprehensive income, net of tax, attributable to parent      44
Comprehensive loss, net of tax, attributable to parent:(185,170)(127,072)(92,106)(84,768)(45,794)(29,072)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: